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Abstract
Objective—(a) To establish whether the
cognitive decline of the early phase of
relapsing-remitting multiple sclerosis de-
pends on the progression of the burden of
disease, or on the loss of brain paren-
chyma, or is influenced by both; (b) to
monitor the loss of brain parenchyma in
the early phase of the disease; and (c) to
examine its possible relation with the pro-
gression of physical disability.
Methods—For 2 years 53 patients with
clinically definite relapsing-remitting
multiple sclerosis with disease duration
1–5 years and expanded disability status
scale<5.0 at baseline were monitored. The
neuropsychological performances, the
psychological functioning, the neurologi-
cal impairment, and the disability have
been assessed at baseline and after 2 years.
Patients also underwent PD/T2 and T1
weighted brain MRI. T2 and T1 lesion vol-
umes were measured by a semiautomatic
technique. Quantification of brain paren-
chymal volumes was obtained using a
highly reproducible computerised inter-
active program. The relation between
cognitive impairment and MRI findings
has been investigated by partial correla-
tion and stepwise multiple regression
analyses excluding the eVects of age, edu-
cation, anxiety, depression, and total days
of steroid use.
Results—In the 2 years of the study the
mean change for T2 and T1 lesion volumes
and brain parenchymal volumes were +1.7
ml (95% confidence interval (95% CI) 1.3–
2.2, p=0.005, (29.8%); +0.2 ml, 95% CI
0.15–0.26, p=0.004, (25%); and –32.3 ml,
95% CI 24.2–42.3, p<0.0001, (2.7%), re-
spectively. Overall, 14 patients (26.4%)
were judged to be cognitively impaired at
baseline and 28 (52.8%) at the end of the
follow up. Of the 18 neuropsychological
tests and subtests employed in the study,
patients with multiple sclerosis failed 5.8
(SD 2.3) tests at the baseline and 8.4 (SD
2.9) (p<0.0001) tests at the end of the
study. When the cognitive changes were
examined in individual patients, five
(9.4%) of them were considered cogni-
tively improved, 33 (62.3%) remained
stable, and 15 (28.3%) worsened over 2
years. T2 and T1 volume changes in
improved, stable, and worsened patients
did not show any significant diVerence,
whereas brain parenchymal volume de-
crease in cognitively worsened patients
was significantly greater (−66 ml (5.4%),
95% CI 37–108.9, p=0.0031). The cognitive
impairment was independently predicted
over 2 years only by the change of brain
parenchymal volumes (R=0.51, p=0.0003).
Ten patients (18.9%), who worsened by
one or more points in the EDSS during
the follow up period had significant de-
creases in brain parenchymal volumes
(−99 ml (8%), 95% CI 47.6–182.3, p=0.005).
At the end of the study the loss of brain
parenchyma correlated significantly with
change in EDSS (r= 0.59, p<0.0001).
Conclusions—In the early phase of
relapsing-remitting multiple sclerosis the
cognitive deterioration relies more on the
development of brain parenchymal vol-
ume atrophy than on the extent of burden
of disease in the brain. The loss of brain
parenchymal volume underlies the pro-
gressive accumulation of physical disabil-
ity from the initial phase of the disease,
which becomes more demonstrable only if
studied with longer observation periods.
Probably, the main pathological substrate
of brain atrophy in the early stage of the
disease is early axonal loss, which causes
the progression of neurological deficits
and the development of cognitive impair-
ment. These data support the debated
opinion that disease modifying therapy
should be initiated as early as possible.
(J Neurol Neurosurg Psychiatry 2001;70:773–780)
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DiVerent MRI techniques for monitoring
disease evolution in patients with multiple
sclerosis have been widely employed in thera-
peutic clinical trials.1–4 Protocols for MRI are
now routinely incorporated in such studies,
providing powerful evidence of a therapeutic
eVect and extending clinical findings. Conven-
tional and non-conventional MRI techniques
have also been used to demonstrate a relation
between MRI abnormalities and cognitive dys-
function in many cross sectional studies.5–18
Only a few longitudinal studies examined the
correlation between MRI abnormalities and
patterns of cognitive impairment.5 19–21 None of
these studies involved patients with multiple
sclerosis in the early stages of the disease and
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most of them used only conventional MRI
techniques and qualitative or manual quantifi-
cation postimaging analysis methods. Data
from more recent studies indicate that cogni-
tive disturbances can be present early in the
clinical evolution of the disease but also that
they may not be obvious.22 23
Recently, several cross sectional studies
demonstrated that the pathogenesis of cogni-
tive impairment in patients with multiple scle-
rosis does not depend only on the extent and
severity of the pathological process within
brain lesions, but also on the microscopic
pathological changes aVecting the normal
appearing brain tissue.7 9–11 18 In fact, the new
technologies employed in pathological and
MRI studies showed that progressive patho-
logical changes occur far earlier in the disease
process than previously thought, and that
widespread abnormalities can develop early in
the brain parenchyma.24–31
The recent demonstration of early irrevers-
ible axonal transection25 in multiple sclerosis
led us to conduct a longitudinal study designed
to monitor the cognitive performances and the
changes shown by diVerent conventional and
non-conventional MRI techniques in 53 pa-
tients with early phase relapsing-remitting
multiple sclerosis over 2 years. The aim of the
study was to establish whether the cognitive
decline depends on the progression of the bur-
den of disease, or on the loss of brain
parenchyma, or it is influenced by both.
Relatively few longitudinal natural history
MRI studies of cerebral atrophy in multiple
sclerosis have been reported to date.32–35 None
of these studies evaluated the progression of
cerebral atrophy in the early phase of relapsing-
remitting disease. So, the secondary objective
of our study was to monitor the loss of brain
parenchyma in the early phase of the disease
and to test its relation with the progression of
physical disability.
Material and methods
PATIENTS
Eighty three consecutive unselected patients
aVected by definite multiple sclerosis according
to the diagnostic criteria proposed by Poser et
al,36 participated in the study. The study
involved patients who were being seen in
routine follow up, or for problems not related
to cognitive disturbances or disease exacerba-
tion.
To assess the attention and the compliance
to attend the proposed battery of tests and the
ability to follow the scheduled protocol for 2
years, we decided to screen our multiple
sclerosis population with two tests before the
complete evaluation of their neuropsychologi-
cal capacities. The screening was performed
using the mini mental state examination
(MMSE)37 and the standard Raven progressive
matrices (SRPM)38 adjusted for age, sex, and
educational level. Arbitrarily we decided to
choose a cut oV value of>24 for MMSE and
the 15th percentile for SPRM. Inclusion crite-
ria were definite multiple sclerosis, relapsing-
remitting disease course, age 18–60 years, dis-
ease duration 1–5 years, EDSS score<5.0,39
and written informed consent from all the
patients. Exclusion criteria were MMSE
score<24; SRPM<15th percentile; concomi-
tant disorders (cerebrovascular disease, neuro-
degenerative disorder, positive history of alco-
hol misuse, severe visual deficit, or severe upper
limb motor impairment), or pre-existing psy-
chiatric or psychological disorders that, them-
selves, can cause cognitive dysfunction or can
impede the completion of the cognitive tests;
concurrent exacerbation of the disease; and
immunomodulating, steroid, or psychoactive
drug treatment in the 3 months preceding the
entry to the study. During the follow up period
the patients with multiple sclerosis were
checked for the appearance of concomitant
disorders which could influence the cognitive
performances. During the study period, treat-
ment with disease modifying therapy was not
used in any enrolled patient. Corticosteroid
administration was allowed in cases of exacer-
bation at the discretion of each patient’s
neurologist.
A neurologist (RZ) specialised in multiple
sclerosis care classified patients as having
relapsing-remitting multiple sclerosis accord-
ing to the disease course criteria recently pub-
lished by Lublin and Reingold.40 The exacerba-
tions were defined as the appearance or
reappearance of one or more symptoms attrib-
utable to multiple sclerosis, accompanied by
objective deterioration lasting at least 24 hours
on neurological examination, in the absence of
fever, and preceded by neurological stability for
at least 30 days and in the absence of steroid
withdrawal within 60 days of the new event.
Thirty patients (19 women and 11 men)
were excluded from the study. Reasons of
exclusion were secondary or primary chronic
progressive disease course (eight patients), IQ
less than the 15th percentile on SRPM
adjusted for age, sex, and educational level (five
patients), severe visual deficits or severe upper
limb motor impairment (four patients), steroid
treatment in the preceding 3 months (four
patients), history of alcohol misuse (three
patients), immunomodulating drug treatment
in the preceding 3 months (two patients), psy-
choactive drug treatment in the preceding 3
months (two patients), MMSE<24 (one pa-
tient), refusal to participate in the study (one
patient). Hence, the remaining 53 patients, 37
(69.8%) women and 16 (30.2%) men, partici-
pated in the present study.
Our data could not represent the real preva-
lence of cognitive disturbances in the early
phase of relapsing-remitting multiple sclerosis
because we choose to screen our population
with MMSE and SPRM before inclusion in the
study to check their attention, compliance, and
ability to sustain a 2 year follow up study.
All patients had a full neurological examina-
tion at baseline and at the end of follow up. The
neurological impairment, the disability, and the
independence of the patient have been
measured using the EDSS and the functional
independence measure (FIM).41 At the end of
the study the patients were classified as
clinically worsened if they decreased at least
1.0 EDSS score point from the baseline status.
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NEUROPYCHOLOGICAL EVALUATION
Within 48 hours of MRI examination, the same
extensive neuropsychological battery of tests
used at baseline was readministered to the
patients at the end of the 2 year follow up. The
battery comprised measures of attention/
concentration/information processing speed,
memory function, abstract/conceptual reason-
ing, visuoperceptual skills, verbal intelligence,
and language skills. We specifically chose tests
that do not require fine visual acuity or motor
speed/dexterity.
The attention/concentration/information pro-
cessing speed was assessed by the 3 second per-
formance of the paced auditory serial addition
test (PASAT),42 the colour/word-word condi-
tions of the Stroop colour word interference test
(STROOP)43 and the subtest of the Wechsler
adult intelligence scale-revised (WAIS-R; verbal
fluency)44. Memory was tested by the two
subtests of the WAIS-R (digit span forward and
feedback) and by the subtest of the Bilingual
aphasia test (BAT; story recall test)45. Abstract/
conceptual reasoning skills were evaluated by
SRPM. Visuoperceptual skills were evaluated
using the cube subtest of the WAIS-R. Verbal
intelligence was assessed by means of the
similarities subtest of the WAIS-R and the men-
tal arithmetic subtest of the BAT. The linguistic
parameters chosen for the evaluation were
syntactic comprehension of mistakes, semantic
mistakes, and syntactical and morphological
mistakes. The numbers of verbal paraphasias,
neologisms, and agrammatisms as a measure of
linguistic property and ability were assessed by
means of the BATs. These tests are routinely
used in the assessment of cognitive impairment
in multiple sclerosis and are extensively de-
scribed elsewhere.46–48
At the baseline and at the end of the follow
up, the number of failed tests was calculated for
each patient. According to previously pub-
lished criteria49 established cut oV scores to
indicate impairment (table 1) have been used.
Patients have been considered aVected by
overall cognitive impairment if they obtained
abnormal results in two or more cognitive
domains. At the end of the study we decided to
classify the patients according to their cognitive
status as follows:
(a) Cognitively improved patients—Patients
who presented more than 25% of improvement
from the baseline status in the neuropsycho-
logical tests exploring at least two or more cog-
nitive domains, and who simultaneously had
not worsened more than 25% in the tests
exploring other cognitive domains.
(b) Cognitively worsened patients—Worsening
required a 25% decline from baseline tests
scores exploring at least two or more cognitive
domains, without 25% simultaneous improve-
ment in the tests exploring other cognitive
domains.
(c) Cognitively stable patients—Patients not
meeting the above mentioned criteria were
classified as stable.
This classification, used also in a longitudi-
nal study performed by Hohol et al5 had been
chosen so that each patient could serve as his or
her own comparison and control for eVects of
age, sex, and education. The requirement that
at least two changes in cognitive domains by
25% from baseline status was based on the
results of previous studies in the early phase of
multiple sclerosis50 51
The Hamilton depression rating scale
(HDRS)52 and the Hamilton anxiety rating
scale (HARS)53 were employed, after a psychi-
atric interview with the patient to exclude psy-
chological disorders which can contribute to
cognitive disturbances, and were repeated at
the end of the follow up.
MAGNETIC RESONANCE IMAGING
Image acquisition
Brain MRI was performed at baseline and at
the end of the follow up on a Philips Gyroscan
S 15 ACS II 1.5 tesla unit. Axial images of the
brain were obtained with 5 mm slice thickness
using PD/T2 weighted SE sequences (TR
Table 1 Neuropsychological scores of patients with relapsing-remitting multiple sclerosis at baseline and at the end of follow
up testing. The cut oV scores indicating impairment are provided
Cut oV
scores
Baseline
(53 patients)
mean (SD)
Follow up
(53 patients)
mean (SD)
Mean % change
(95% CI) p Value
Stroop colour word interference test (ms) >69 71.3 (5.4) 81.9 (9.4) 14.9 (11.2–19.5) <0.0001
Paced auditory serial addition test <48 47.9 (11.1) 42.3 (15.7) 11.7 (8.8–15.3) 0.035
Standard Raven progressive matrices >110 119.5 (13.7) 113.8 (13) 4.8 (3.6–6.3) 0.033
Wechsler adult intelligence scale
Verbal fluency (total No) <34 36.7 (9.5) 33.1 (10.3) 9.8 (7.3–12.8) 0.064
Digit span forward <5 5.1 (1) 4.4 (1.3) 13.7 (10.3–17.9) 0.003
Digit span feedback <4 2.8 (1.1) 2.8 (0.8) 0 (—) 0.839
Similarities (No correct) <11 8.3 (2.3) 7.1 (1.5) 14.5 (10.9–19) 0.002
Cube subtest <10 8.3 (1.5) 7.5 (1.3) 9.6 (7.2–12.6) 0.003
Bilingual aphasia test
Story recall test (No of errors) >2 1.1 (0.9) 1.5 (1.6) 36.4 (27.2–47.7) 0.099
Mental arithmetic (No of errors) >2 1.5 (1.7) 2.7 (2.4) 80 (60–104.8) 0.048
Morphology (No of errors) >5 2.9 (3.5) 4 (3.2) 37.9 (28.4–49.6) 0.091
Syntax (No of errors) >14 9.3 (6.8) 14.1 (11) 51.6 (38.6–67.6) 0.008
Semantic (No of errors) >7 3.5 (3.3) 4.7 (3.3) 34.3 (25.7–44.9) 0.05
Syntactic comprehension (No of errors) >12 14 (9.1) 15 (10.3) 7.2 (5.4–9.4) 0.590
Spontaneous speech (No of errors)
Verbal paraphasias >1 1 (1) 3.7 (1.5) 270 (202.2–353.7) <0.0001
Agrammatisms >2 3.6 (3.2) 4 (2) 11.1 (8.3–14.5) 0.489
Neologisms 0 0.3 (0.9) 0.1 (0.3) 66.6 (49.9–87.2) 0.402
Mini mental state examination >24 29.4 (1) 29.2 (1.4) 0.68 (0.51–0.89) 0.366
Hamilton depression rating scale 5.6 (6.7) 6.4 (7) 14.2 (10.7–18.6) 0.574
Hamilton anxiety rating scale 21.4 (22.2) 22.9 (21.2) 7 (5.2–9.2) 0.727
Comparison between the baseline and the follow up was performed by paired t test.
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2709/TE 20–80) and unenhanced T1 weighted
CSE sequences (TR 600/TE 27). A matrix of
179×256 pixels has been used for a total of 24
sections. Field of view was 220 mm. Patients
were positioned in the magnet according to
European Community guidelines.54
Image analysis
Two investigators, blinded to the patient’s
clinical characteristics and the cognitive tests
results (RDM and ND), performed the image
analysis at baseline and at the end of the study
on a Sun Ultra 5 Promo workstation (Sun
Microsystems, Mountain View, CA, USA).
Imaging data have been transferred directly to
the computer system of the medical imaging
processing group by a home developed net-
work transferring system. Lesion load was cal-
culated using a highly reproducible local
thresholding technique for lesion segmenta-
tion.55 56 The lesions were first outlined on PD
weighted hard copies on each axial slice (T2
weighted scans were always used to increase
confidence in lesion detection). The measure-
ments of lesion area were then performed on
computer displayed images by the same
observers, keeping the marked hard copies as a
reference. A conservative approach for the cal-
culations of lesions in T1 weighted images was
used. A hypointense lesion was defined as any
region visible on the T1 weighted sequence
with a low signal intensity between those of the
CSF and grey matter and corresponding to a
region of high signal intensity on the T2
weighted sequence. Lesions were delineated as
regions of interest (ROIs) and the volume was
simply calculated for each sequence by multi-
plying the total ROI area by the slice thickness.
The results are expressed in ml.
The evaluation of brain atrophy was per-
formed on T1 weighted CSE sequences meas-
uring the brain parenchymal volumes. An
interactive home developed program which
incorporates semiautomatic and automatic
segmentation processes was used for the meas-
urements. The whole brain parenchyma vol-
ume was analysed (from the cerebral hemi-
spheres and the other supratentorial structures
to the cerebellum and the brain stem). A ster-
eoatactic atlas was used as a reference for seg-
menting the diVerent brain structures. Firstly,
the external edge of whole brain parenchyma
was determined by semiautomatic iterative
morphological scalping of the external brain
surface. Then, the automatic segmentation of
the CSF spaces and brain parenchyma was
performed using a knowledge based automatic
segmentation algorithm for histogram thresh-
olding analysis. This segmentation process
automatically creates brain parenchyma only
( 1 A and C) and CSF only (fig 1 B and D)
images and calculates the volumes for brain
parenchyma and CSF. To determine the repro-
ducibility of the method, 10 patients with mul-
tiple sclerosis and 10 sex and age matched
healthy volunteers had two separate MR scans
within 1 week. Reproducibility was calculated
as a coeYcient of variation (CV) (100%×SD/
mean) between the repeated measurements, by
two investigators blinded to patient details and
diagnosis. The mean CV for brain parenchymal
volumes in this group was 0.39% (range 0.09–
0.56) for between observer reproducibility and
0.37% (range 0.09–0.52) for within observer
reproducibility. This clearly indicates the ex-
tremely high precision of the segmentation
method.
STATISTICAL ANALYSIS
Statistical analysis was performed with the Sta-
tistical Package for the Social Sciences (SPSS,
version 10.0). For comparisons between
groups the ÷2 test, paired t test, and analysis of
variance (ANOVA) were used, as appropriate.
Cognitively improved, stable, and worsened
patients with multiple sclerosis at the end of the
follow up have been compared using ANOVA
adjusted for age, sex, years of education,
anxiety, depression, and total days of steroid
use. The relation between cognitive impair-
ment and MRI changes at baseline and at the
end of the follow up has been investigated by
partial correlation coeYcient analysis cor-
rected for multiple comparisons and by multi-
variate stepwise linear regression analysis
(backward selection model) excluding the
eVects of age, education, anxiety, depression,
and total days of steroid use. For the
correlation and multiple regression analyses we
created an overall cognitive deterioration com-
posite score from the 18 neuropsychological
tests employed. For each patient, the results
from all the neuropychological tests were
scored using a standardised method49 based on
a comparison with the percentile distribution
of values in a large group of Italian subjects.
These scores ranged from 0 to 4, where grade 0
means a very poor performance and grade 4
means a normal performance. Individual test
scores were then summed to provide an overall
cognitive deterioration composite score for
each patient. The minimum significance level
for entry and for staying in the equation was
0.05. All p values were based on two tailed
tests.
Results
The study consisted of 53 patients (37 women
and 16 men) aVected by the relapsing-
remitting form of multiple sclerosis. Mean age,
disease duration, and educational level at base-
line were 30.2 years (SD 9.4; range 21–58
years), 3.8 years (SD 1.3; range 1–5 years), and
11.3 years (SD 3.2; range 8–17 years), respec-
tively. Mean annual relapse rate over the 2 years
before the patients’ entrance in the study was
1.0 (SD 1.8; range 0–6). Mean EDSS score at
baseline was 1.6 (range 0–5.0), median EDSS
score at baseline was 1.0. Mean FIM score at
baseline was 125.7 (range 121–126), median
FIM score at baseline was 126. At the end of
the follow up period we did not find significant
diVerences from baseline data for any of the
clinical variables, except for disability (mean
EDSS 1.8, median EDSS 1.5, p=0.007). Total
days of steroid use during the follow up was 9.7
(SD 6.5; range 5–16).
Initial and follow up neuropsychological
performances are listed in table 1. Overall, 14
patients (26.4%) were judged as cognitively
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impaired at baseline and 28 (52.8%) at the end
of the follow up. Of the 18 neuropsychological
tests and subtests employed in the study,
patients failed 5.8 (SD 2.3; range 1–12) at
baseline and 8.4 (SD 2.9; range 3–15), at the
end of the follow up (p<0.0001). When the
cognitive changes were examined in individual
patients, five (9.4%) were considered cogni-
tively improved, 33 (62.3%) remained stable,
and 15 (28.3%) worsened after the 2 year fol-
low up. The cognitively improved, stable, and
worsened patients were studied according to
the demographic and clinical data. We did not
find any significant diVerence between the
three groups except for the educational level,
which was higher in the cognitively improved
group (p=0.018). Compared with the baseline
status the patients did not present significant
changes for depression and anxiety at the end
of the study.
Baseline loads of multiple sclerosis lesions
visible on T2 and T1 weighted scans, baseline
brain parenchymal volumes, and changes in
these MRI parameters over 2 years are shown
in table 2. During the follow up period the
patients showed a significant increase in lesion
loads and a decrease in brain parenchymal vol-
umes, which was more evident for loss of brain
parenchyma (p<0.0001). Changes inT2 and
T1 volume in improved, stable, and worsened
patients did not show any significant diVer-
ence, whereas the decrease in brain parenchy-
mal volume in cognitively worsened patients
was significantly higher (−66 ml (5.4%), 95%
CI 37–108.9; p=0.0031). A correlation analy-
sis performed to verify whether the loss of brain
parenchymal volume in cognitively worsened
patients was age dependent failed to show a
relation between these two variables (r=0.22,
p=0.513).
The 10 patients (18.9%), who worsened by
on or more points in the EDSS during the fol-
low up period, had a significant decrease in
brain parenchymal volumes (−99 ml (8%),
95% CI 47.6–182.3; p=0.005). The change in
disability rate was not significant for changes in
T2 and T1 lesion volumes over the 2 years.
Figure 1 Brain parenchyma only (A and C) and CSF only (B and D) images in a 32 year old man with early
relapsing-remitting multiple sclerosis (A and B show baseline acquisition and C and D acquisition at study completion)
who worsened in his cognitive performance over 2 years of follow up. The loss of brain parenchyma, as reflected by the
enlargement of ventricles and sulci was 4.3%.All the patients completed the designed protocol for clinical,
neuropsychological, and radiological testing in the follow up period. Only two patients had their MRI examination at the
end of the study 48 hours after the neuropsychological testing. Additional MRI examination were performed on some
patients at the time of clinical exacerbation, but these examinations were not taken into account in the follow up study.
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Overall cognitive impairment did not corre-
late significantly with any of the demographic,
clinical, or MRI variables at baseline. At the
end of the follow up period only the decrease in
brain parenchymal volumes was significantly
related to changes in cognitive performances
(r=0.31, p=0.0031). Brain parenchymal vol-
ume correlated significantly with T2 and T1
lesion loads at baseline (r=0.33, p=0.021 and
r=0.37, p=0.008), respectively. The relation
between the changes in these variables became
more robust after 2 years (r= 0.61, p<0.0001
and r=0.78, respectively, p<0.0001). Moreo-
ver, at the end of the study the change of brain
parenchymal volume correlated significantly
with changes in EDSS (r=0.59, p<0.0001),
FIM (r=0.33, p=0.022), and, weakly, with
annual relapse rate over 2 years (r=−0.29,
p=0.043). Other significant correlations were
detected at the end of the follow up period
between changes in T1 lesion load, changes in
EDSS, and duration of disease (r=0.47,
p=0.001 and r=0.29, p=0.045), respectively,
and between changes in T2 lesion load and
changes in EDSS (r=0.38, p=0.007).
We developed several multiple regression
models using the overall cognitive deterioration
and the brain parenchymal volume as depend-
ent variables. The cognitive impairment was
independently predicted over 2 years only by
the mean absolute change of brain parenchy-
mal volumes (R=0.51, p=0.0003). The loss of
brain parenchyma was independently corre-
lated with T1 lesion load at baseline (R=0.59,
p<0.0001) and to the mean absolute change of
T1 lesion load and the change in EDSS at the
end of the follow up (R=0.69, p<0.00001 and
R=0.81, p<0.0001, respectively).
Discussion
To the best of our knowledge this is the first
longitudinal study of brain atrophy and cogni-
tive performances conducted on a homogene-
ous group of patients not treated with disease
modifying agents in the early phase of
relapsing-remitting multiple sclerosis.
Few longitudinal studies have explored the
relation between the cognitive status and the
MRI parameters. These studies19–21 used inac-
curate postimaging analysis techniques to
measure the burden of disease and did not
focus attention on the microscopic damage of
brain parenchyma. Only one longitudinal
correlation study using non-conventional MRI
techniques, has been carried out.5
Our study, performed on relatively young
patients with short disease duration, demon-
strated that a remarkable part of the study
population had global cognitive worsening.
These data suggest that cognitive decline
occurs early in the course of the disease and
that over 2 years the patients can develop a
sustained progression of the impairment of
their cognitive performances.
Some patients improved in their follow up
neuropsychological performances. As the same
tests were used at the baseline and at the end of
the follow up, a potential learning eVect which
may also have masked a more severe cognitive
deterioration over time in the remaining
patients can be hypothesised. In our opinion
however, the complexity of the battery of tests
used and the period of follow up, too long to
show “imprinting” capacities of memory rein-
forcement in execution of tests, make unlikely a
lasting eVect of practice.57
Compared with the cognitively improved
and stable patients, the 15 patients considered
cognitively worsened at the end of the study
showed a more conspicuous decrease of brain
parenchymal volumes than an increase of T2
and T1 lesion loads. These data, supported by
the findings of Hohol et al5 who demonstrated,
in a heterogeneous group of patients with mul-
tiple sclerosis during a 1 year follow up, that the
rapid development of brain atrophy deter-
mined substantial cognitive decline, were
strengthened also by the partial correlation and
multiple regression analyses results which
showed that the change in cognitive perform-
ances over 2 years was only and independently
predicted by the decrease of brain parenchymal
volume.
As previously reported by other authors,5 19–21
in our longitudinal study we did not find any
significant relation between overall cognitive
impairment and clinical variables such as
disability, relapse rate, or duration of disease.
We showed that over 2 years the patients
worsened in all MRI parameters, but that the
progression was more evident for the loss of
brain parenchymal volume, although we de-
tected a statistically significant increase also for
T2 and T1 lesion loads. Seven patients had
negative T2 lesion volume change at comple-
tion of the study. The mean increase of 29.8%
in T2 lesion volume at the end of the follow up
is higher than that reported in previous MRI
serial studies58 and the data from a recently
published CHAMPS study59 reported, in the
placebo group, a median percentage change of
T2 lesion volume around 17% during the 18
month follow up. The diVerences in duration of
disease and in the duration of observation
between these studies and ours may perhaps
explain the diVerent results. In table 2 we
reported that the mean rate of brain atrophy
was 1.33%/year. This rate was slightly higher
Table 2 Baseline T2 and T1 lesion loads and brain
parenchymal (BP) volumes and changes over 2 years in
patients with relapsing-remitting multiple sclerosis
Baseline
(53 patients)
Follow up
(53 patients) p Value
T2 lesion load (ml): 0.005
Mean (SD) 5.7 (5.9) 7.4 (7)
Range 0.02–29.9 0.23–27
T2 change over 2 y:
Mean (%) +1.7 (29.8)
(95% CI) (1.3–2.2)
T1 lesion load (ml) 0.004
Mean (SD) 0.8 (1.1) 1 (1.1)
Range 0–5.3 0–5.3
T1 change over 2 y:
Mean (%) +0.2 (25)
(95% CI) (0.15–0.26)
BP volume (ml) <0.0001
Mean (SD) 1219.1 (76.8) 1186.8 (80.7)
Range 1054.1–
1306.3
981.9–1289.2
BP change over 2 y:
Mean (%) −32.3 (2.65)
(95% CI) (24.2–42.3)
Comparison between the baseline and the follow up was
performed by paired t test.
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than those reported recently by other
authors31–33 indicating that brain atrophy could
be one of the primary pathological events in
early disease development and progression.
Other studies performed recently with diVer-
ent MRI and pathological techniques which
explored the normal appearing brain tissue
pointed out that microscopic diVuse brain
damage could be responsible in part for the
development of the physical disability.24–31 Over
2 years our patient population showed sus-
tained progression of disability. In the patients
who deteriorated by one or more points in the
EDSS (10 patients) over 2 years, the loss of
brain parenchymal volume was pronounced.
Moreover, the partial correlation and multiple
regression analyses showed a relation between
brain parenchymal volume change and EDSS
change over the follow up period. These
findings disagree with the data recently pub-
lished by Gee et al32 and by Fox et al.33 These
authors found a poor correlation between the
change in EDSS and the rate of atrophy over 1
year, and speculated that probably such a
period was not long enough to allow the dem-
onstration of an association between increasing
brain atrophy and changes of EDSS.
Although it is clear that the axonal loss and
the demyelination contribute predomi-
nantly24 25 to the loss of brain parenchyma in
the advanced phases of the disease, it is still
unsettled which of the white or grey matter
components are firstly involved in the early
stages and to what degree. Our study results
suggest that the strong relation found after 2
years between neurological impairment and
loss of brain parenchyma could be explained
early in disease development by the same
pathological substrate: the axonal damage
which leads irreversibly to neuronal drop out.
These data are also supported by the findings
of partial correlation analysis, which showed
significant correlation coeYcients between
brain parenchymal volume and T2 and T1
lesion loads at baseline, which became more
robust at the end of the study. The change in
T1 lesion load (a direct marker of axonal loss)
was the only variable along with the EDSS,
which independently predicted the change in
brain atrophy. Probably, a 1 year period was not
long enough to point out an association
between progressive cerebral atrophy and
change in EDSS, as suggested in previous
studies.31 33
The recent findings of irreversible axonal
transection early in the course of multiple scle-
rosis provided further evidence supporting the
importance of early treatment. Use of disease
modifying therapy for multiple sclerosis has a
demonstrable slowing eVect on dysfunction.60
Rudick et al61 demonstrated that patients with
relapsing-remitting disease on interferon â-1a
therapy had a significant reduction in the pro-
gression of brain atrophy during the second
year of treatment. Our results indicate that the
loss of brain parenchyma in the early stages of
relapsing-remitting multiple sclerosis is one of
the essential factors responsible for progression
of physical disability and cognitive deteriora-
tion. Therefore, the early use of disease modi-
fying therapy in clinically asymptomatic pa-
tients without remarkable physical disability,
but presenting subtle cognitive changes could
be reasonable.
In conclusion, we suggest that in the early
phase of relapsing-remitting multiple sclerosis
cognitive deterioration relies more on the
development of brain parenchymal atrophy
than on the extent of disease burden in the
brain. The loss of brain parenchymal volume
underlies the progressive accumulation of
physical disability since the initial phase of the
disease, and becomes evident only if studied
with longer observation periods. Probably, the
brain atrophy is caused by the diVuse and early
axonal loss, which reflects the progression of
neurological deficits and the development of
cognitive impairment. These data support the
debated opinion that the disease modifying
therapy should be initiated as early as possible.
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